Blue Clay Capital Management’s Horizon Therapeutics Public Limited Company Ordinary Shares HZNP Stock Holding History

Blue Clay Capital Management’s Portfolio HZNP Stock Details HZNP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q3	$587K	Buy	32,390 +1,390	+4%	+$27.2K	0.66%	37
2016 Q2	$511K	Buy	+31,000	New	+$502K	0.59%	45

Other funds holding HZNP

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

KCM

Kingdon Capital Management New York $911M AUM 51.11% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

HealthCor Management New York $109M AUM 10.64% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Blue Clay Capital Management's HZNP Position: Q3 2016 in Review

Blue Clay Capital Management increased its Horizon Therapeutics Public Limited Company Ordinary Shares (HZNP) stake by 4.5% in Q3 2016, buying an estimated $27.2K and bringing the position to 32,390 shares worth $587K. The position accounts for 0.66% of the portfolio, ranked #37.

Blue Clay Capital Management first reported a position in HZNP in Q2 2016 and has held it in 2 quarters since. 232 funds tracked by Wall St. Rank hold HZNP as of Q3 2016.

Blue Clay Capital Management held 32,390 shares of Horizon Therapeutics Public Limited Company Ordinary Shares worth $587K as of Q3 2016.
Blue Clay Capital Management bought 1,390 Horizon Therapeutics Public Limited Company Ordinary Shares shares in Q3 2016, an estimated $27.2K.
Horizon Therapeutics Public Limited Company Ordinary Shares made up 0.66% of Blue Clay Capital Management's portfolio in Q3 2016, its #37 holding.
Blue Clay Capital Management first reported a position in Horizon Therapeutics Public Limited Company Ordinary Shares in Q2 2016 and has held it in 2 quarters since.
232 funds tracked by Wall St. Rank held Horizon Therapeutics Public Limited Company Ordinary Shares as of Q3 2016.

Based on Blue Clay Capital Management's 13F filing for Q3 2016, filed 14 Nov 2016.